Praxis Precision Medicines
PRAX
143 hedge funds and large institutions have $1.02B invested in Praxis Precision Medicines in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 65 increasing their positions, 35 reducing their positions, and 32 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 35
70% more call options, than puts
Call options by funds: $26.3M | Put options by funds: $15.5M
14% more capital invested
Capital invested by funds: $889M → $1.02B (+$126M)
2.26% more ownership
Funds ownership: 116.31% → 118.57% (+2.3%)
5% less funds holding
Funds holding: 150 → 143 (-7)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$39.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.4M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$13.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$37.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$32.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.68M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.59M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.94M |
PRAX Hedge Fund Activity: Q2 2025 in Review
143 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2025, worth a combined $1.02B — up 14% from $889M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of PRAX and 25 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 65 added.
The largest buyer was Janus Henderson Group, adding an estimated $39.1M. The largest seller was VR Adviser, exiting entirely with an estimated $37.5M sold.
- 143 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2025, down from 150 in Q1 2025.
- Funds reported $1.02B of Praxis Precision Medicines stock for Q2 2025, up 14% quarter-over-quarter.
- 25 funds opened new Praxis Precision Medicines positions in Q2 2025 and 32 closed out, a net change of -7 holders.
- The largest Praxis Precision Medicines buyer in Q2 2025 was Janus Henderson Group, an estimated $39.1M added.
- The largest Praxis Precision Medicines seller in Q2 2025 was VR Adviser, an estimated $37.5M sold.
Based on aggregated 13F filings for Q2 2025.